WuXi XDC Cayman (HKG:2268) expects a net profit of 260% higher in 2024 than in 2023, a Wednesday Hong Kong bourse filing said.
The company also expects its revenue for the reporting year to jump 85% compared with the year prior.
The antibody-drug conjugates company attributed the surge in its expected net profit and revenue for the reporting period to steady downstream demand from the fast growth of antibody-drug conjugate and the expanded bio-conjugate industry.
The group also attributed the higher gains for 2024 to its competitive strength and increased profit margins for the reporting period resulting from improved production efficiency.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。